Amendment to the Claims

In the claims:

In accordance with the provisions of 37 C.F.R. § 1.121(c), please amend the claims as follows:

Claim 1-45. (Previously Canceled)

Claim ~~46~~ 45. (Currently Amended): An immunological adjuvant composition useful for enhancing the immune response against an active agent, comprising:

a first adjuvant consisting essentially of amorphous calcium phosphate particles; and

a liquid component,

said ~~first~~ adjuvant composition formulated as an injectable paste having a solids content of greater than or equal to 40 wt%.

Claim ~~47~~ 46. (Currently Amended): An immunological adjuvant composition useful for enhancing the immune response against an active agent, comprising:

a first adjuvant comprising amorphous or nanocrystalline calcium phosphate particles; ~~and~~

a liquid component; and

an active agent selected from the group consisting of antigens, bacteria or viruses or fragments thereof, haptens, allergens and immunogens,

said ~~first~~ adjuvant composition formulated as an injectable paste having a solids content of greater than or equal to 40 wt%. ~~;and an active agent selected from the group consisting of antigens, bacteria or viruses or fragments thereof, haptens, allergens and immunogens.~~

Claim ~~48~~ 47. (Previously Added): The composition of claim ~~46~~ 45 or ~~47~~ 46, wherein said particles have a diameter between 0.1 nm and 900 nm.

Claim ~~49~~ 48. (Previously Added): The composition of claim ~~48~~ 47, wherein 25-100% by weight of said composition consists of said particles having a diameter between 0.1 nm and 900 nm.

Claim 49 (~~50~~). (Previously Added): The composition of claim 45 (~~46~~) or 46 (~~47~~) further comprising a second adjuvant.

Claim 50 (~~51~~). (Previously Added): The composition of claim 49 (~~50~~), wherein said second adjuvant is selected from the group consisting of muramyl dipeptide, aluminum hydroxide, aluminum phosphate, hydroxyapatite, Incomplete Freund's Adjuvant, and Complete Freund's Adjuvant.

E14 E6 Cont

Claim 51 (~~52~~). (Previously Added): The composition of claim 49 (~~50~~), wherein the first and second adjuvants are selected so as to elicit an immune response from targeted cells or cell types.

Claim 52 (~~53~~). (Previously Added): The composition of claim 49 (~~50~~), wherein the first and second adjuvants are selected so as to elicit an immune response from cells of the same type.

Claim 53 (~~54~~). (Previously Added): The composition of claim 49 (~~50~~), wherein the first and second adjuvants are selected so as to elicit an immune response from cells of different types.

Claim 54 (~~55~~). (Previously Added): The composition of claim 49 (~~50~~), further comprising an endogenous adjuvanticity enhancing means.

Claim 55 (~~56~~). (Previously Added): The composition of claim 46 (~~47~~) wherein the active agent comprises an antigen.

Claim 56 (~~57~~). (Previously Added): The composition of claim 46 (~~47~~) further comprising a cytokine.

Claim 57 (~~58~~). (Previously Added): The composition of claim 45 (~~45~~), wherein said cytokine is selected from the group consisting of IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-11, IL-13, G-CSF, IL-15, GM-CSF, OSM, LIF, IFN-γ, IFN-α, IFN-β, B7.1, B7.2, TNF-α, TNF-β, LT-β, CD40 ligand, Fas ligand, CD27 ligand, CD30 ligand, 4-1BBL, IL-8, MCP-1, MIP-α, MIP-β, RANTES, TGF-β, IL-1α, IL-1β, IL-1 RA, IL-10, IL-12, and MIF.

Claim 58 (~~59~~). (Previously Added): The composition of claim 46 (~~47~~), wherein the nanocrystalline calcium phosphate comprises hydroxyapatite.

Claim 59 (~~60~~). (Previously Added): A method for stimulating an immune response in a mammal, said method comprising:

E14 Cont'd

administering to the mammal a composition comprising amorphous or nanocrystalline calcium phosphate particles and an active agent selected from the group consisting of antigens, bacteria or viruses or fragments thereof, haptens, allergens and immunogens, formulated as an injectable paste having a solids content of greater than or equal to 40 wt%.

Claim ~~61~~ 60. (Currently Amended): A method for increasing immunogenicity of an antigen in a mammal, said method comprising:

co-administering both an antigen and a composition comprising amorphous calcium phosphate formulated as ~~a hardenable~~ an injectable paste having a solids content of greater than or equal to 40 wt%.